T2 Biosystems to Present at the Morgan Stanley Global Healthcare Conference

LEXINGTON, Mass., Sept. 2, 2014 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (Nasdaq:TTOO) today announced that John McDonough, president and chief executive officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10, 2014, at 1:30 p.m. E.T. in New York City.

A live, listen-only webcast of the presentation may be accessed by visiting the investors section of the company's website at www.t2biosystems.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the company's website for 30 days following the presentation.

About T2 Biosystems

T2 Biosystems is an in vitro diagnostics company that is using its T2 Magnetic Resonance platform, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, and can detect cellular targets at limits of detection as low as one colony-forming unit per milliliter, or CFU/mL. T2 Bio's initial development efforts utilizing T2MR target sepsis and hemostasis, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics. For further information, visit the company's website at http://www.t2biosystems.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our status as a development-stage company and our expectation to incur losses in the future; our ability to obtain marketing authorization from the Food and Drug Administration, or FDA, or regulatory clearance for T2Dx diagnostic instrument, T2Candida panel and our other product candidates in the United States or any other jurisdiction; the market acceptance of our T2MR technology; our ability to timely and successfully develop and commercialize our existing and future product candidates; the length of our anticipated sales cycle; our ability to gain the support of leading hospitals and key thought leaders and publish the results of our clinical trials in peer-reviewed journals; our future capital needs and our need to raise additional funds; the performance of our diagnostic product candidates; our ability to successfully manage our growth; our ability to compete in the highly competitive diagnostics market; our ability to protect and enforce our intellectual property rights, including our trade secret-protected proprietary rights in our T2MR technology; and federal, state, and foreign regulatory requirements, including FDA regulation of our product candidates. These and other important factors discussed under the caption "Risk Factors" in our final prospectus filed with the Securities and Exchange Commission, pursuant to Rule 424(b) of the Securities Act of 1933, as amended, on August 7, 2014, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

CONTACT: Media Contact: Dan Budwick, Pure Communications dan@purecommunicationsinc.com 973-271-6085 Investor Contact: Matt Clawson, Pure Communications matt@purecommunicationsinc.com 949-370-8500

Source:T2 Biosystems, Inc.